{"a":[{"_":"Vertex, in its largest-ever deal, acquires endocrine disease specialist Crinetics for $10B ","$":{"href":"/pharma/vertex-acquires-endocrine-disease-specialist-crinetics-10b","hreflang":"en"}}]}
PalsonifyatumelnantPositive
AI Analysis
Summary
Vertex Pharmaceuticals announced a $10 billion acquisition of Crinetics Pharmaceuticals, Vertex's largest deal ever, to gain two endocrine disease drugs (Palsonify and atumelnant) with combined peak sales potential exceeding $5 billion.
Outcome Details
$10 billion acquisition deal completed
Importance:9/10
Sentiment:
0.70
M&Aacquisitionendocrine diseaseVertexCrineticslargest deal
Read the original article
Published by FiercePharma on July 7, 2026 7:17 AM